Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth hormone therapy in adults with Prader-Willi syndrome: muscle tone by fMRI
2017-002164-41Phase 4Active
- Sponsor
- Fundació Parc Taulí
- Start
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of somatropin in Prader-Willi syndrome (PWS), sponsored by Fundació Parc Taulí. Primary endpoint: Muscle tone with functional magnetic resonance imaging (fMRI). Started Jun 2017; status: active.
02
Drugs
somatropin
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on 2017-002164-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002164-41.